Introduction
Hepatocellular carcinoma (HCC) is already the fifth most prevalent human malignancy worldwide and shows increasing incidence (El-Serag, 2002) . In more than 80% of all cases, a well-defined etiology (e.g. viral infection, chronic alcohol abuse) is associated with its development. Because the current therapeutic options for HCC patients are sobering, there is a great need to analyse molecular oncogenic mechanisms in order to determine novel targets for specific systemic therapy. There is vast evidence for protumorigenic growth factor signaling dysregulation in human HCCs affecting different signaling systems such as Insulin-like Growth Factor (IGF)-, Hepatocyte Growth Factor (HGF)-, Wingless (Wnt)-, Transforming Growth Factor a (TGFa)/Epidermal Growth Factor (EGF)-and Transforming Growth Factor b (TGFb) signaling. Therefore, these factors, their receptors and associated downstream signaling cascades represent prominent therapeutic targets. Growth factors exert their multiple, partially overlapping functions (mitogenic, motogenic, antiapoptotic and angiogenic) in a para-/autocrine manner via transmembranous receptors. Ligand binding results in receptor activation with phosphorylation of cytoplasmic components and induction of several signaling cascades. As growth factor signaling is instrumental for normal embryogenesis and organ development as well as tissue regeneration and repair, these pathways ( Figure 1 ) are tightly regulated at several levels. Dysregulation of these factors and their pathway components has been connected with essential tumor properties such as tumor cell proliferation, antiapoptosis neo-angiogenesis, invasive behavior and chemotherapy resistance. This review focuses on the molecular and functional changes as well as the potential networks/cross-talks of these pathways in human hepatocarcinogenesis and the resulting therapeutic potential.
Signaling pathways and their dysregulation
Insulin-like Growth Factor signaling axis The IGF signaling pathway is of central relevance in embryogenesis as well as lifespan regulation, and exhibits potent proproliferative and antiapoptotic properties. Key regulatory molecules of this axis are small ligands (IGF-I and IGF-II, 7-8 kDa), IGF binding proteins (IGFBP1-6) and membrane-bound receptors (IGF-1 receptor (IGF-1R), as well as the mannose-6-phosphate receptor (IGF-II/M6PR, IGF-2R)). Bioavailability of both IGFs is influenced by the presence of secreted IGFBPs (Murphy, 1998) as well as IGF-2R, which directs IGFs to lysosomal degradation (Braulke, 1999) . However, the system is far more complex, as both ligands not only bind to their conventional receptors (IGF-1R (Esposito et al., 1997) and IGF-2R) but also to the insulin receptor (isoform A, INSR; Frasca et al., 1999) , and INSR/IGF-16F-1R hybrid molecules (Sakai and Clemmons, 2003) . After ligand binding, rapid phosphorylation of distal intracellular targets commences specific cellular downstream effectors such as INSR-substrates IR5 (IRS1,2,4), leading to the activation of, for example, phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT/PKB; Figure 1 ). Moreover, binding of the growth factor receptor-bound protein 2 (Grb2) leads to the activation of the Raf/ mitogen-activated protein kinase family (MAPK) signaling pathway. Together, this regulatory network results in the transcriptional activation of numerous target genes including p27 kip1 , MYC, FOS, cyclin B and Vascular Endothelial Growth Factor (VEGF); (reviewed by Foulstone et al., 2005) .
As far as we know, dysregulation of IGF signaling in HCC predominantly occurs at the level of IGF-II bioavailability. This potent growth factor is highly expressed in fetal liver, but strongly downregulated after birth. Its transcriptional regulation is complex and comprises four different tissue-specific and epigenetically regulated promoters (P1-P4; Vu and Hoffman, 1994) , and two polyadenylation signals (Sussenbach et al., 1992) . Although the physiological function of lowlevel IGF-II expression in adult liver has largely remained obscure, there is a large body of evidence for multiple protumorigenic functions during hepatocarcinogenesis such as antiapoptosis, stimulation of proliferation and activation of angiogenesis. IGF-II is overexpressed in 16-40% of human HCCs (Table 1) , and possibly even in some premalignant lesions (Cariani et al., 1988; Ng et al., 1998; Aihara et al., 1996; Sohda et al., 1996; Breuhahn et al., 2004) , in HCC cell lines (Li et al., 1997; Breuhahn et al., 2004; Lund et al., 2004) and in several HCC animal models (Schirmacher et al., 1991 (Schirmacher et al., , 1992 Harris et al., 1998) . Elevated expression in HCC cells results from transcriptional activation such as loss of promoter-specific imprinting or re-activation of the fetal promoter (P2-P4) pattern (Li et al., 1997; Vernucci et al., 2000) . In keeping with the activation of the IGFaxis, IRS-1 (Nishiyama and Wands, 1992) and IRS-2 (Boissan et al., 2005) are frequently elevated in human HCCs. In vitro IGF-II treatment of IGF-II-overexpressing HCC cell lines has no functional effects, indicating maximal autocrine stimulation. This observation is further supported by the progressive accumulation of unbound, active IGF-II in HCC cell supernatants.
Figure 1 Schematic and simplified display of different growth factor signaling pathways frequently involved in the development and progression of human hepatocellular carcinogenesis (IGF/IGF-1R, HGF/MET, TGFa/EGFR, Wnt/FZD, and TGFb/TbR) and their potential cross-talks. Predominantly dysregulated signaling components are highlighted in dark gray. Seldom regulated components (e.g. Smad2), molecules not expressed by tumor cells (e.g. HGF) and distinct protein familiy members dysregulated in HCCs (e.g. FZD-7) are highlighted in light gray. AKT/PKB: protein kinase B; APC: adenomatosis polyposis coli; DG: diacylglycerol; DSH: dishevelled; EBP50: ezrin-radixin-moesin binding phosphoprotein 50; Elk: member of Ets oncogene family; Gab1: GRB2-associated binding protein 1; Grb2: growth factor receptor-bound protein 2; GSK3b: glycogen synthase kinase 3 beta; HDPR1: dapper homolog 1; IRS: insulin receptor substrate; LEF: lymphoid enhancer-binding factor; MEK1: mitogen-activated protein kinase kinase 1; PI3K: phosphatidylinositol 3-kinase; PIN1: prolyl cis/trans isomerase; PIP 2 : phosphatidylinositol bisphosphate; PKC: protein kinase C; PLC: phospholipase C; RSTTK: receptor serine/threonine kinase; RTK: receptor tyrosine kinase; Shc: (Src homology 2 domain containing) transforming protein; Smad: mothers against DPP homolog; Sos: son of sevenless; Stat: signal transducer and activator of transcription; TCF: transcription factor.
Inhibition of IGF-II in HCC cells reduces cell proliferation, increases apoptosis and improves chemotherapy response (Lund et al., 2004) , whereas IGF-II overexpression correlates with high proliferation in HCC animal-models (Schirmacher et al., 1992) .
In hepatitis B virus (HBV)-and hepatitis C virus (HCV)-associated HCCs, a possible mechanistic link between potentially oncogenic viral proteins and the IGF-II level in HCC cells has been described (Park et al., 1995; Nardone et al., 1996) . The HBV-derived HBx protein in particular has been shown to increase IGF-II expression, presumably owing to SP1-mediated reactivation of fetal-type IGF-II promoters Kang-Park et al., 2001) . The HCV-derived core gene product also acts as a transactivator and therefore induces expression of IGF-II from P4 through SP1 and EGR-1 binding sites . However, elevated IGF-II levels owing to the presence of viral infections may represent a premalignant phenomenon as IGF-II expression correlates with HBV-and HCVinduced cirrhosis (Tanaka et al., 1996; Sedlaczek et al., 2003) . Although a constitutive overexpression of IGF-1R in HCCs was not described, a correlation between IGF-1R gene expression and the presence of HBx protein has been proposed in HCC cell lines (Kim et al., 1996) .
IGF-II bioavailability may also in part be regulated through IGF-2R; downregulation or deletion of this receptor should theoretically lead to locally increased concentrations of IGF-II molecules. Expression of IGF-2R has been described to be reduced in 63% of human HCC (Sue et al., 1995) . Moreover, loss of heterozygosity at the igf-2r locus has been published for HCCs and its premalignant lesions (De Souza et al., 1995a; Oka et al., 2002) , whereas inactivating mutations of the second allele have been detected in about 25% of the cases (De Souza et al., 1995b) . Additionally, several missense mutations in the extracytoplasmic domain of IGF-2R efficiently disrupt receptor/ligand interaction, which is then followed by increased ligand bioavailability Devi et al., 1999) . However, these results are still controversially discussed, as other studies failed to detect any genetic alterations at the igf-2r locus (Wada et al., 1999; Saeki et al., 2000; Enomoto et al., 2001) , which might be owing to methodical or populationbased differences.
More than 70% of IGF-II is bound to IGFBP3, the most abundant circulating binding protein for IGFs (1996) , Noguchi et al. (1996) , Neaud et al. (1997) , Guirouilh et al. (2000 Guirouilh et al. ( , 2001 ) MET Upregulated in 20-48% Boix et al. (1994) , Suzuki et al. (1994) , Kiss et al. (1997) , Ueki et al. (1997) , Tavian et al. (2000) TGFa (Jones and Clemmons, 1995) . Thus, downregulation of IGFBPs may contribute to elevated IGF bioavailability in tumor tissues. Indeed, expression of IGFBP1, -3 and -4 have been described to be frequently reduced in HCCs (Gong et al., 2000; Huynh et al., 2002) . In addition, IGF-independent IGFBP functions on cell motility, cell cycle and apoptosis (Firth and Baxter, 2002; Mohan and Baylink, 2002) and the ability to concentrate IGFs near their receptor, consequently improving IGF bioactivity, are currently discussed. However, none of these hypotheses has been proven for HCC cells so far.
Wingless/b-catenin signaling axis The Wnt signaling pathway is an evolutionary highly conserved pathway and involved in the regulation of proliferation, motility, cell/cell interaction, organogenesis and axis formation (reviewed by Wodarz and Nusse, 1998; Kikuchi, 2003 Behrens and Lustig, 2004) . Combined with low-density lipoprotein receptor-related protein 5/6(LRP 5/6), the FZD receptor leads to differential phosphorylation of dishevelled (DSH), which in turn inhibits amino-terminal serine/threonine phosphorylation of cytoplasmic b-catenin by casein kinase-1a/e and glycogen synthase kinase-3b (GSK-3b). The tumor suppressor proteins axin-1/axin-2 and adenomatous polyposis coli (APC) interact with these kinases and facilitate phosphorylation of b-catenin, recognition of the E3-ubiquitin ligase receptor b-TrCP, polyubiquitination and subsequent proteasomal degradation. In addition to this canonical degradation, an alternative pathway involving the p53-inducible E3-ubiquitin ligase seven in absentia homolog (SIAH) has been described, which permits b-catenin degradation independent of its phosphorylation status (Polakis, 2001 ). Stabilized, non-degraded b-catenin accumulates in the nucleus, forms complexes with LEF/TCF transcription factors and recruits chromatin-remodeling proteins such as CBP/p300 leading to the expression of numerous transcriptional targets. These Wnt/b-catenin targets include gene products responsible for proliferation (e.g. MYC), antiapoptosis (e.g. survivin), invasion (e.g. matrix metalloproteinases (MMPs)) and angiogenesis (e.g. VEGF). Thus, the activation of Wnt targets not only regulates tissue development and regeneration but it can also influence tumor growth and progression in the case of aberrant nuclear accumulation of b-catenin.
Depending on the study in 17-40% of human HCCs exhibit a nuclear accumulation of b-catenin (Nhieu et al., 1999; Hsu et al., 2000; Wong et al., 2001; Prange et al., 2003) . Somatic APC mutations, which lead to an aberrant concentration of b-catenin, as shown in, for example, colon carcinomas (Ficari et al., 2000) , have seldom been described in HCCs. Instead, nuclear accumulation is in part explained by stabilizing point mutations and deletions in the N-terminal phosphorylation domain of b-catenin, which is observed in 19-44% of all cases (de La Coste et al., 1998; Miyoshi et al., 1998; Cui et al., 2003; Prange et al., 2003; Fujito et al., 2004) . In addition, mutational inactivation by deletions, missense and nonsense mutations has been described for axin-1 (5-14%), predominantly in the region responsible for b-catenin and GSK-3b interactions (Satoh et al., 2000; Ishizaki et al., 2004) . Equally, axin-2 (Conductin), which also contains binding sites for b-catenin and GSK-3b, exhibits mutations in 3-10% of the HCCs (Taniguchi et al., 2002; Ishizaki et al., 2004) .
Several additional factors have been described to increase b-catenin bioavailability and bioactivity in hepatocarcinogenesis. For example, PIN1 (a prolyl cis/ trans isomerase), which has been shown to inhibit bcatenin/APC interaction (Ryo et al., 2001) , is upregulated with subsequent accumulation of b-catenin in more than 50% of all HCCs (Pang et al., 2004) . Ezrinradixin-moesin binding phosphoprotein 50 (EBP50), on the other hand, elevates b-catenin/TCF-mediated transcription (Shibata et al., 2003) . Equally, FZD-7 is frequently overexpressed in HCCs (Merle et al., 2004) . Dapper homolog 1 (HDPR1), an inhibitor of DSH, has been described to be downregulated in 58% of HCCs associated with the accumulation of b-catenin (Yau et al., 2005) . Lastly, DKK-1 and -3, potential inhibitors of Wnt signaling, are dysregulated to a different extent in HCCs; however, the biological function of DKK in hepatocarcinogenesis is currently unclear (Wirths et al., 2003; Hsieh et al., 2004) . It is also worth mentioning that several studies do not show a correlation between the nuclear accumulation of b-catenin and the expression of several canonical transcriptional targets in HCCs (e.g. cyclin D1; Inagawa et al., 2002; Joo et al., 2003; Prange et al., 2003) . Thus, tumor-entity-specific expression pattern and differential protumorigenic molecular mechanisms of the Wnt pathway (e.g. in colon vs. hepatocellular carcinogenesis) have to be considered (Prange et al., 2003) .
Taking these data together, it is likely that more than one single factor of the Wnt/b-catenin pathway has to be dysregulated in an individual liver tumor to achieve aberrant b-catenin enrichment. An explanation for this situation may be the fact that nuclear enrichment is not mandatory for stabilized b-catenin. In support of this theory, b-catenin can be tagged for proteasomal degradation without proper phosphorylation by SIAH E3-ubiquitin ligase family members (Liu et al., 2001a; Matsuzawa and Reed, 2001) . According to this model, phosphorylation of b-catenin is not sufficient for efficient ubiquitin-mediated protein destruction. Thus, in some cases accumulation of stabilized b-catenin may exert selective pressure on Wnt pathway components (e.g. SIAH-1 (Matsuo et al., 2003) and EBP50) not involved in the phosphorylation of b-catenin. Whether or not this functional link is also of relevance in HCCs remains to be explored.
Transforming Growth Factor b signaling axis
The TGFb superfamily of polypeptide growth factors includes TGFbs (TGFb-1-3), Bone Morphogenetic Proteins (BMPs), nodals, activins, and other related factors, which are highly conserved throughout evolution (Massague, 1998) . Equally, a group of the so-called type II (e.g. TGFb receptor type II (TbR-II)) and type I (e.g. TGFb receptor type I (TbR-I)) receptors have been described that contain extracellular binding domains and intracellular serine/threonine kinase domains (Massague, 1998). Additionally, a third receptor molecule (TbR-III) does not have intrinsic signaling function but mediates ligand/TbR-II/TbR-I interaction. After secretion, TGFb is activated proteolytically (e.g. by the M6P/ insulin like growth factor II receptor) and binds to TbR-II, which in turn leads to the recruitment and transphosphorylation of TbR-I. Afterwards, the transcription factors Smad2 and Smad3 (R-Smads) are recruited to the receptor complex and become activated via phosphorylation (Figure 1 ). This results in their release from the receptor, heterodimerization with the signal mediator Smad4 and subsequent translocation into the nucleus (Liu et al., 1997) . Here receptor-activated Smads and Smad4 form complexes with potential co-regulators of transcription such as CBP/p300 (Feng et al., 1998) , FAST-1 (Chen et al., 1997) and SKI/SNO (Liu et al., 2001b) . The composition of these transcriptional complexes is believed to be largely responsible for the celltype-specific effects of TGFb. The transcriptional targets of TGFb include genes that are involved in negative feedback regulation such as the inhibitory Smad7, which participates in targeting TbR-I for ubiquitin-dependent degradation (Nakao et al., 1997; Kavsak et al., 2000) .
TGFb is a potent growth inhibitor for hepatocytes; therefore, inhibition of TGFb-signaling is believed to be a central pathway that has to be impaired during human hepatocarcinogenesis. Conversely, TGFb serum and urine levels are increased in patients with HCC (Tsai et al., 1997; Kim et al., 2000) . Immunohistochemically, it has been demonstrated that TGFb is upregulated in up to 40% of HCCs (Bedossa et al., 1995; Abou-Shady et al., 1999) . Moreover, expression levels of the receptors are published as unchanged (Abou-Shady et al., 1999), up-(TbR-I; Musch et al., 2005) , and downregulated (TbR-II (Sue et al., 1995; Kiss et al., 1997; Musch et al., 2005) ; TbR-I (Sue et al., 1995) ) in HCCs as compared to adjacent liver tissue; overall, most studies document a reduction of the receptors in HCCs (up to 70%).
One explanation for this bewildering situation may be bifunctional properties of TGFs. Although TGFb has been suggested to inhibit hepatocyte proliferation, a tumor-promoting/proinvasive role depending on the presence of oncogenic Ras has been shown (Gotzmann et al., 2002) . Moreover, not only the presence of the ligands but the ratio between both TbR-I and TbR-II influences the cellular fate of a given signal (receptor degradation vs signal transduction; Huang and Huang, 2005) . These data may explain that TGFb serum and urine levels are increased in patients with HCC (Tsai et al., 1997; Kim et al., 2000) . High TGFb levels correlate with decreased median survival and have even been proposed as a serologic marker to support detection of HCCs (Song et al., 2002; Okumoto et al., 2004) .
The Smad-mediated signaling cascade, which is impaired in other carcinomas (e.g. ductal pancreatic adenocarcinoma with Smad4 mutations in about 50%), seems to be intact in the vast majority of human HCCs. Smad2 mutations (o5%) and loss of Smad4 expression (10%) are infrequent molecular events (Yakicier et al., 1999; Longerich et al., 2004) . Smad3 mutations have not been described in human hepatocarcinogenesis yet; however, recently published data clearly show a physical interaction between Smad3 and the HCV core protein, consequently antagonizing DNA-binding capacity of Smad3 and therefore reducing TGFb-dependent signaling (Cheng et al., 2004; Pavio et al., 2005) . Furthermore, the inhibitory Smad7 has been found to be upregulated in about 60% of advanced HCCs, but not in dysplastic nodules and early HCCs (Park et al., 2004) . Combined, these data suggest that the TGFb signaling axis is impaired on a functional and not on a structural level in hepatocarcinogenesis. The structural integrity might be beneficiary for HCC cells, as protumorigenic aspects of the TGFb pathway such as tumor cell migration are preserved.
In contrast, the other TGFb superfamily members have only rarely been investigated in human HCCs. Whereas BMP signaling is not related to HCC development, similarities with classical TGFb signaling have been suggested in activin signaling during human hepatocarcinogenesis, which also depends on Smads as downstream effectors. Patients with HCCs exhibit elevated serum levels of activin (Yuen et al., 2002) .
Hepatocyte Growth Factor/MET signaling axis The HGF (scatter factor) is the most potent growth factor for hepatocytes and binds to its only known highaffinity receptor MET. This receptor tyrosine kinase (RTK) is predominantly expressed on epithelial and endothelial cells and regulates proliferation (Efimova et al., 2004) , migration (Monvoisin et al., 1999) , cell survival (Suzuki et al., 2000) , morphogenesis , angiogenesis (Schmidt et al., 1995) , as well as tissue regeneration (Borowiak et al., 2004) . Hepatocyte growth factor binding and MET multimerization results in receptor auto-and paraphosphorylation of adaptor proteins (e.g. Gab-1 and Grb2; Figure 1) , followed by the activation of cytoplasmic downstream effectors (e.g. phospholipase C (PLC)g, Stats, PI3K and extracellular signal-regulated kinase (ERK)1/2; reviewed by Stuart et al., 2000) . Specificity of the HGF/ MET signaling axis is achieved through the presence of unique adaptors (Gab-1; Sachs et al., 2000) and the interaction with various membranous binding partners (e.g. b4-integrins; Trusolino et al., 2001) . Subsequent activation of distinct transcription factors (e.g. Ets-1 and activator protein-1; Johnson et al., 1995; Paumelle et al., 2002) leads to the expression of numerous target genes (e.g. MMPs and urokinase-type plasminogen activator (uPA); Sato et al., 1995; McCawley et al., 1998; Jiang et al., 2001; Monvoisin et al., 2002; Ozaki et al., 2003) .
MET is detectable in most HCCs (B70%; Table 1 ; Suzuki et al., 1994; Kiss et al., 1997) ; however, overexpression of the receptor as compared to peritumorous liver tissue is observed in a lower number of tumor samples (20-48%; Boix et al., 1994; Suzuki et al., 1994; Kiss et al., 1997; Ueki et al., 1997; Tavian et al., 2000) . This induction in HCC cells may be attributed to different molecular mechanisms, such as genomic alterations (7q gains in 16.8%; Moinzadeh et al., 2005) , tumor hypoxia (Pennacchietti et al., 2003) and growth factor-dependent transcriptional activation of MET (e.g. by HGF; Seol et al., 2000) . In addition, somatic mutations in the tyrosine kinase domain have been detected in childhood HCCs (30%) but not in adult HCCs (Park et al., 1999) . Furthermore, receptor transactivation by EGF receptor (EGFR) and RON (Follenzi et al., 2000; Jo et al., 2000) or cell/cell contact ) represent potential molecular mechanisms for ligand-independent activation of this signaling pathway. Similarly, HGF has been shown to be over represented in HCCs as compared to the normal liver; however, it is not expressed by tumor cells themselves (Selden et al., 1994; Noguchi et al., 1996) . Instead stellate cells and myofibroblasts are induced to secrete HGF by tumor cell products and HGF in turn stimulates tumor cell invasiveness (D'Errico et al., 1996; Neaud et al., 1997; Guirouilh et al., 2000 Guirouilh et al., , 2001 . Whether this indirect, paracrine interaction is sufficient to exert protumorigenic effects in vivo remains unclear. Hepatocyte growth factor is secreted in an inactive proform, which needs proteolytic cleavage for full bioactivity. Therefore, bioavailability of pro-HGFactivating proteins such as HGF activator inhibitor type 1 (Nagata et al., 2001 ) and uPA (De Petro et al., 1998) are required for ligand-induced onset of the HGF/ MET signaling axis.
In the majority of the studies, increased levels of MET in HCCs do not correlate with tumor size or invasive behavior (Boix et al., 1994; Okano et al., 1999) ; however, one study links the expression of MET with increased intrahepatic metastasis and decreased 5-year survival of patients (Ueki et al., 1997) . Additionally, overexpression of MET is detected predominantly in poorly differentiated HCCs (Daveau et al., 2003) . Although one study does not demonstrate a correlation of HGF expression levels with patient survival or clinicopathological parameters (Ueki et al., 1997) , recently published data show that higher HGF serum levels negatively correlate with patient survival time (Vejchapipat et al., 2004) and positively correlate with tumor size (Yamagamim et al., 2002) .
Transforming Growth Factor a/Epidermal Growth Factor signaling axis
The TGFa/EGF cytokine family includes several ligands that bind to the EGFR. In humans, at least eight known ligands for EGFR have been described: TGFa, EGF, heparin-binding EGF, amphiregulin, betacellulin, epiregulin, epigen and crypto. These growth factors represent a family of transmembrane-anchored molecules, which can be cleaved by ectodomain (proteolytic) shedding (e.g. by tumor necrosis factor-a-converting enzyme a disintegrin and metalloproteinase domain 17 (TACE/ADAM17); Sunnarborg et al., 2002) . This process regulates, for example, bioavailability (and therefore bioactivity) of the ligands and signal duration (Massague and Pandiella, 1993) . The tyrosine receptor kinase family consists of four known members (EGFR (Her1/ErbB-1), neu/Her2/ErbB-2, Her3/ErbB-3 and Her4/ErbB-4). Upon ligand binding, the receptors form either homo-or heterodimers and initiate signal transduction.
Depending on the kind of ligand and its concentration differential phosphorylation of multiple tyrosine residues at the intracytoplasmic portion of the molecule has been described (Guo et al., 2003) . This receptor region in turn serves as a docking site for recruitment of proteins with Src homology 2 domains such as Grb2 and Shc, which activate multiple downstream pathways (Figure 1 ). For EGFR, several distinct signaling pathways have been described, which can be directly or indirectly activated by specific MAPK kinases (e.g. ERK, JUN NH2-terminal kinase (JNK), p38 mitogen-activated protein kinase (p38-MAPK) and ERK5). Whereas MEK1/2 activates ERK1/2, MKK3/6 is responsible for p38 phosphorylation, MKK4/7 regulates JNK MAPKs and MEK5 is responsible for ERK5 activation (reviewed by Chang and Karin, 2001 ). This network is further complicated by several regulatory feedback mechanisms (Sugiura et al., 2003; Sweeney and Carraway, 2004) .
TGFa and EGF stimulate hepatocellular DNA synthesis and act as potent mitogens for hepatocytes (Mead and Fausto, 1989; Rescan et al., 2001) . Overexpression of TGFa is frequently observed in human HCCs and patients suffering from HCC may have elevated urinary TGFa levels (Yeh et al., 1987; Chuang et al., 1991) . TGFa is also expressed at high levels in HCC cell lines and all downstream signaling components have been described to be structurally intact (Hisaka et al., 1999) . However, the published data are not unequivocal, as immunhistochemical analyses of TGFa also found decreased protein levels in HCCs (Table 1) as compared to surrounding non-tumorous liver tissue (Kiss et al., 1997) . Because staining intensity of TGFa does not necessarily represent ligand bioactivity (proteolytic shedding of membrane-bound TGFa by, for example, ADAMs), the immunhistochemistry may still depict inactive TGFa in the liver tissue and bioactive (cleaved) TGFa in the tumor. In addition, TGFa seems to act during the early stages of hepatocarcinogenesis and has been described to correlate with tumor differentiation and proliferation (Kira et al., 1997; Zhang et al., 2004) . Interestingly, accumulation of pro-TGFa has recently been found in human and rat hepatocyte nuclei suggesting a direct role of pro-TGFa in mitosis (Grasl-Kraupp et al., 2002) . Furthermore, pro-TGFa concentrations increase from normal liver over premalignant lesions to HCCs (Schausberger et al., 2004) .
Heparin-binding EGF, which has been shown to be a more potent mitogen for hepatocytes than EGF, can be detected immunohistologically in 59-100% of HCCs, but not or only weakly in the surrounding parenchyma (Inui et al., 1994) . Heparin-binding EGF expression appears to be a prognostic marker for disease-free survival and thus may be involved in early hepatocarcinogenesis (Ito et al., 2001a) .
The receptors EGFR/ErbB-1 (Nakopoulou et al., 1994; Kira et al., 1997; Ito et al., 2001b) , neu/Her2/ ErbB-2 (Nakopoulou et al., 1994; Ito et al., 2001b) , Her3/ErbB-3 (Ito et al., 2001b) and Her4/ErbB-4 (Ito et al., 2001b) are expressed in HCCs; however, staining frequency and intensity of the tumor tissues in comparison to the surrounding non-tumorous liver tissues differ between these studies (Table 1) . It is noteworthy that in contrast to other carcinomas (e.g. breast cancer), amplification of the ErbB2 gene is considered uncommon in human HCCs (Prange et al., 2003; Xian et al., 2005) .
Multiple links between chronic HBV infection and expression of TGF signaling components have been described. Firstly, intracellular TGFa co-localizes with the HBV-surface antigen (pre-S1) in liver tissues with chronic HBV infection, presumably owing to nonspecific retention in the endoplasmatic reticulum by pre-S1 (Schirmacher et al., 1996) . Secondly, in HCC cells HBV-DNA induces TGFa expression . Thirdly, TGFa levels in HCCs correlate with the presence of viral polypeptide (HBs and HBc) in the adjacent non-tumorous liver tissues . Whether this is owing to HBx-mediated transactivation of TGFa promoter activity is currently unknown (Kim and Rho, 2002) .
Cross-talk with protumorigenic factors
Potential cross-talks of the different growth factor signaling pathways with each other and with other protumorigenic factors have been shown to promote tumor growth and tumor progression. Functions of distinct signaling pathways can be amplified (e.g. increased proliferation) and even novel protumorigenic qualities may be acquired and might further facilitate tumor progression (e.g. via p53-mediated chromosomal stability/instability). In turn, the bioactivity of growth factor pathways may be the target of other oncogenic pathways (e.g. p53-induced expression of growth factor components).
Interaction of growth factor signaling with other oncogenic pathways Cyclooxygenase (COX)-2 catalyses the enzymatic conversion of arachidonic acid to prostaglandins (e.g. prostaglandin E2 (PGE 2 )) and is frequently overexpressed in HCCs Bae et al., 2001) . Cyclooxygenase-2 also interacts with several growth factor pathways (reviewed by Wu, 2006) . Elevated COX-2 levels may be owing to IGF-II/IGF-1R-mediated induction of COX-2 expression as was already shown in colon carcinoma cells (Di Popolo et al., 2000) . Vice versa, selective inhibition of COX-2 bioactivity by non-steroidal anti-inflammatory drugs (NSAIDs; for example, celecoxib) leads to reduced IGF-1R expression in HCC cells (unpublished own data), which may in part explain the observed proapoptotic effects of celecoxib on these cells (Kern et al., 2002 (Kern et al., , 2004 .
Nuclear accumulation of b-catenin and mutant Ras increase COX-2 expression in HCC cell lines, followed by elevated PGE-2 level in the cell culture supernatant (Araki et al., 2003) . Because there is evidence for the existence of Ras mutations in rare vinyl chloridedependent HCCs (Weihrauch et al., 2001a, b) , the combination of nuclear b-catenin enrichment and K-RAS mutations may account for the induction of COX-2 in a small subgroup of HCCs.
Hepatocyte growth factor induces the expression of COX-2 and synthesis of PGE 2 in gastric mucosa cells (Chen et al., 2005) . In turn, it has been shown that COX-2/PGE 2 activates the MET signaling axis via transactivation of EGFR in HCC cells (Han et al., 2006. In HCC cells, selective NSAIDs such as NS-398 reduce HGF-mediated effects such as invasiveness and expression of MMPs (Abiru et al., 2002) .
There are also multiple interactions of growth factor signaling pathways with p53, a central regulator of apoptosis, cell cycle and genomic stability (reviewed by Sherr and McCormick, 2002) . Loss of function as well as gain of function of p53 by point mutations, deletions or interaction with viral proteins enable cancer cells to escape p53-dependent growth control.
In vitro IGF-II promoter activity and protein biosynthesis is repressed by p53 wt (Zhang et al., 1996; Lee et al., 2000) , whereas the aflatoxin-induced p53 mutation (p53 mut (249) ) markedly induces IGF-II accumulation through enhanced formation of transcriptional complexes in HCC cells and increases IGF-1R expression in HCC cells . However, as IGF-1R overexpression was not described in human HCCs, further regulatory elements may inhibit IGF-1R enrichment in vivo. In addition, induction of IGFBP-3 expression by p53 wt but not by p53 mut suggests that regulation of IGF-II bioavailability is a relevant effector mechanism of p53 in hepatocarcinogenesis (Buckbinder et al., 1995) . A significant correlation between the nuclear accumulation of p53 (indicative for mutations) and b-catenin has been show (Prange et al., 2003) and several links exist between the p53 pathway and wnt/b-catenin signaling in HCC cells to explain this phenomenon. Firstly, p53-induced SIAH expression may participate in the phosphorylation-independent degradation of bcatenin; however, its relevance in HCCs has not been shown until now (Matsuzawa et al., 1998; Liu et al., 2001a; Matsuzawa and Reed, 2001 ). Secondly, accumulation of b-catenin wt correlates positively with a high exposure of aflatoxin B1 (Devereux et al., 2001 ) and with mutational inactivation of p53 in HCCs (Cagatay and Ozturk, 2002) ; however, a direct connection between all three parameters (aflatoxin intoxication, aflatoxin-specific G/T mutation in p53 mut/249 and bcatenin enrichment) has not been shown so far.
The growth inhibitory and proapoptotic properties of TGFb in HCC cells are at least in part mediated through the dephosphorylation of p53 and subsequent activation of caspase-3. Moreover, the expression of several cell cycle regulators (cyclin-dependent kinases and cyclins) are reduced (Fan et al., 2004) . Thus, inactivation of TGFb signaling might be one possibility for cancer cells to bypass the TGFb-mediated and p53-dependent growth control. A correlation between the downregulation of TbR-II and nuclear p53 has been published independently of these results (Kiss et al., 1997) .
Cross-talk between different growth factor signaling pathways As cytoplasmic downstream components of most growth factor ligand/receptor complexes (e.g. adaptor proteins, kinases and transcription factors) are frequently utilized by more than one signaling pathway, numerous cross-talks and redundancies between these pathways exist (Figure 1 ). There is, for example, rising evidence that TGFb signal transduction is mediated through Smad-independent pathways (reviewed by Derynck and Zhang, 2003) ; however, whether all of these functional links are of relevance in HCC cells remains to be explored. For instance, the TGFa/EGF/ EGFR as well as the HGF/MET signaling axis causes phosphorylation of Smad2 potentially via MAPK (Kretzschmar et al., 1999) . Additional signaling molecules that have been described to interact with the canonical TGFb/Smad signaling axis include p38-MAPK (Bakin et al., 2002) , Rho guanosine triphosphatases (Bhowmick et al., 2001) , PI3K (Bakin et al., 2000) ), protein phosphatase 2A (Petritsch et al., 2000) and probably many more.
In HCC cells, TGFb signaling has been reported to correlate with the nuclear accumulation of b-catenin and epithelial/mesenchymal transition (EMT). Tumor growth factor b induces the expression of snail and slug, two transcription factors that induce EMT via downregulation of E-cadherin . Ecadherin reduction is considered a hallmark of EMT in hepatocarcinogenesis, leading to the nuclear accumulation of b-catenin (Xu et al., 2003) . Consequently, in HCC cells upregulation of snail/slug correlates with the nuclear translocation of b-catenin (Giannelli et al., 2005) .
MET co-immunoprecipitates with EGFR in protein extracts from HCC cells but not in extracts from normal hepatocytes, suggesting a new tumor-specific cross-talk for the activation of HGF/MET signaling by the TGFa/ EGFR axis (Jo et al., 2000) .
A potential link between the EGFR axis and the Wnt/b-catenin pathway has been discussed for some tumor entities (e.g. breast cancer cells; Civenni et al., 2003; Musgrove, 2004) . Recently published data on transgenic mice overexpressing b-catenin strengthen this assumption, as increased b-catenin expression leads to elevated EGFR levels in hepatocytes. Moreover, immunohistological analyses show a high correlation between the expression of nuclear/cytoplasmic b-catenin and EGFR in most hepatoblastomas (Tan et al., 2005) .
Therapeutic approaches
Given the relevance of growth factor signaling pathways in human hepatocarcinogenesis, it is encouraging that numerous experimental strategies aiming these targets are currently under investigation, although most of them still await preclinical and clinical testing. Some pathways offer several opportunities for specific therapeutic intervention (e.g. IGF/IGF-1R signaling with RTK inhibitors, neutralizing antibodies and dominant-negative (dn) receptor isoforms), whereas other signaling cascades lack valid potential target structures until now (e.g. Wnt/FZD signaling).
Receptor tyrosine and serine/threonine kinase inhibitors Different types of RTK inhibitors have been shown to specifically reduce receptor signaling. In the case of IGF-mediated signal transduction, highly specific RTK inhibitors are necessary to discriminate between IGF-1R and INSR (Pautsch et al., 2001) to prevent diabetogenic effects. Several highly selective inhibitors such as tyrphostins (Ohmichi et al., 1993; Parrizas et al., 1997; Blum et al., 2000 Blum et al., , 2003 , NVP-AEW541 (GarciaEcheverria et al., 2004; Scotlandi et al., 2005) , NVP-ADW742 (Mitsiades et al., 2004; Warshamana-Greene et al., 2004 and cyclolignans Vasilcanu et al., 2004; Menu et al., 2005) reduce the activation of IGF-1R and downstream effectors such as AKT/PKB. In vitro as well as in vivo, these substances efficiently reduce tumor cell growth, often in combination with chemotherapeutic agents (Mitsiades et al., 2004; Scotlandi et al., 2005) .
PHA-665752 efficiently reduces MET phosphorylation and the subsequent activation of downstream effectors such as AKT/PKB, Gab-1, PLCg and Stat3. Binding of PHA-665752 to MET results in decreased proliferation, cell motility and invasion of different types of tumor cells; in vivo administration in mice bearing tumor xenografts leads to a marked reduction of tumor volume, probably via intensive cell death (Christensen et al., 2003; Hov et al., 2004) . SU11271, SU11274 and SU11606 block MET receptor autophosphorylation in a dose-dependent manner, followed by a decreased activation of the adapter Gab-1. Treatment with these substances is associated with diminished cell proliferation and cell motility Berthou et al., 2004) . Lastly, SU5416 is an efficient inhibitor of several RTKs such as the VEGF receptor (VEGF-R; (Mendel et al., 2000) . Similarly, phosphorylation of MET and activation of ERK1/2 and AKT/ PKB are reduced after treatment of HCC cells with SU5416 (Wang et al., 2004) .
Equally, inhibition of RTK activity involved in the TGFa/EGFR signaling cascade can be achieved. In HCC cells, ZD1839 (Iressa; Baselga and Averbuch, 2000) , which has been primarily applied in lung and breast cancer efficiently reduces tumor cell growth and induces apoptosis (Hopfner et al., 2004) and appears to inhibit metastatic activity of HCC cells (Ueno et al., 2005) . Also, OSI-774 (erlotinib; Pollack et al., 1999) inhibits tumor cell growth of HCC cells based on elevated apoptosis (Huether et al., 2005b) . In vivo, these data are supported by a recently published clinical trial, which suggest a benefit of specific EGFR inhibition by the RTK inhibitor erlotinib in HCC patients (Philip et al., 2005) . Multiple other potent small molecule inhibitors of TGFa/EGF receptors (reviewed by Arteaga, 2003) such as GW2016 (Rusnak et al., 2001) and CI-1033 (Slichenmyer et al., 2001 ) await testing in HCC cells.
For the TGFb signaling pathway, serine/threonine kinase inhibitors (RSTK) have been developed. The small molecule inhibitor SB-431542 blocks signal transduction of several TGFb family members (e.g. TGFb (Hjelmeland et al., 2004) and activin (Inman et al., 2002) ) followed by reduced phosphorylation and nuclear translocation of Smads and diminished TGFbevoked protumorigenic cellular effects (Halder et al., 2005) . Equally, SD-208 inhibits TGFb-mediated migration and invasion; however, viability and proliferation are not reduced in all the tumor cell models studied so far (Hayashi et al., 2004; Uhl et al., 2004) . Additional small molecule inhibitors of TGFb-signaling such as SB-505124 (DaCosta Byfield et al., 2004) and A-83-01 (Tojo et al., 2005) have been shown to modulate TGF-familymember-mediated signaling, but the applicability of these substances for the treatment of HCC cells has not been shown so far.
The Ras/VEGF-R inhibitor BAY 43-9006 reduces proliferation and angiogenesis in different tumor cells (Lee and McCubrey, 2003) . Moreover, effects of BAY 43-9006 are observed on further (receptor) tyrosine kinases such as VEGF-R2, PDGF-R, c-KIT and FLT-3 (Wilhelm et al., 2004) . Recently published data of a phase II clinical trial with HCC patients are very promising, as 43% of all patients experienced stable disease or tumor shrinkage (in 9%; Onxy-homepage) after treatment with BAY 43-9006.
Other approaches
Neutralizing antibodies against IGF-1R such as alpha-IR3 (Jacobs et al., 1986; Arteaga and Osborne, 1989; Kato et al., 1993; Scotlandi et al., 1998) and CP-751,871 (Cohen et al., 2005) diminish receptor autophosphorylation and subsequent signaling owing to receptor internalization and lysosomal degradation (Hailey et al., 2002; Sachdev et al., 2003) . dnIGF-1R isoforms with deletions in the cytoplasmic tyrosine kinase domain such as dnIGF-1R 950 and dnIGF-1R 952 Min et al., 2003 Min et al., , 2005 and also secreted isoforms like dnIGF-1R 486 and dnIGF-1R 482 (Reiss et al., 1998 (Reiss et al., , 2001 Min et al., 2003) mediate antineoplastic effects based on the induction of tumor cell apoptosis and growth inhibition. Moreover, specific mutations in the important carboxy-terminal domain (Tyr1250 and Tyr1251) and the tyrosine kinase domain (Tyr1131, Tyr1135 and Tyr1136) reduce proliferation, tumor cell survival and migration (Gronborg et al., 1993; Baserga et al., 1997; Brodt et al., 2001) . Several investigators also employed antisense RNA and antisense oligodeoxynucleotide techniques to block IGF-1R synthesis (Trojan et al., 1993; Resnicoff et al., 1994 Resnicoff et al., , 1995 Lafarge-Frayssinet et al., 1997) , leading to increased apoptosis and reduced proliferation. However, an incomplete reduction of IGF-1R expression as well as unwanted effects on INSR levels have been described, which is possibly owing to the poor accessibility of the target transcripts by the oligonucleotides (Bohula et al., 2003) . Besides targeting the bioactivity and bioavailability of IGF-1R, several approaches are aimed to modulate the ligand (IGF-I and IGF-II) expression and bioavailability using antisense techniques (Trojan et al., 1992 (Trojan et al., , 1993 , neutralizing antibodies (Su et al., 1999; Goya et al., 2004; Lund et al., 2004; Miyamoto et al., 2005) and induction of IGF BPs (Martin et al., 1999; Gray et al., 2000; Zi et al., 2000) .
Several approaches for the modulation of HGF/MET signaling in various tumor entities have been published in the last years (e.g. neutralizing antibodies against HGF and MET, expression of antagonistic HGF variants (e.g. NK4), dnMET and decoy receptors; reviewed by Christensen et al., 2005) . Most of them clearly show antineoplastic effects on various tumor cell types in vitro and in vivo such as decreased proliferation, migration and metastasis potential. Some of these experimental approaches such as adenoviral-mediated NK4 expression (Heideman et al., 2005) and antisense techniques have been successfully applied on HCC cells.
Therapeutic options for the modulation of the Wnt pathway are limited. Nonspecific inhibition (bystander effect) has been described for NSAIDs (aspirin and sulindac; Nath et al., 2003; Boon et al., 2004) and the tyrosine kinase inhibitor STI571 (Gleevec; Zhou et al., 2003) . More specific approaches may employ small molecule antagonists that reduce b-catenin interaction to its binding partners (CREB (Emami et al., 2004) and TCF (Lepourcelet et al., 2004) ) as well as antibodies against Wnts (e.g. Wnt-1; Mikami et al., 2005) . Recently, synthetic b-catenin-responsive promoter constructs (CTP4) have been used for adenoviral transfer of therapeutic gene products, which allow the expression of cytotoxic proteins (e.g. diphtheria toxin A) selectively in cells with increased b-catenin transcriptional acivity (Lipinski et al., 2004) .
Several neutralizing antibodies against TGFa/EGF receptors recognize the extracellular ligand binding domain of the molecules (Arteaga, 2003) . Trastuzumab (herceptin; Harries and Smith, 2002) and 2C4 (pertuzumab; Spicer, 2004) , two anti-neu/Her2/ErbB-2 antibodies efficiently block ligand binding and mediate receptor endocytosis (Arteaga, 2001) . However, initial studies did not exhibit any significant benefit of this anti-Her2/neu treatment in HCC patients (Hsu et al., 2002; Xian et al., 2005) , which is in keeping with the lack of significant membranous Her2 expression in HCCs in one study (Prange and Schirmacher, 2001) . In contrast, anti-EGFR/Her1/ErbB-1 antibodies such as cetuximab (erbitux) have recently been shown to inhibit cell cycle progression and induce apoptosis in HCC cells (Huether et al., 2005a) .
Conclusions and future perspectives
Research on growth factors has made great progress over the last few years and has established the essential role and function of these signaling mechanisms in human hepatocarcinogenesis:
1. From many expression analyses in human HCCs, it has become evident that constitutive activation of growth factor signaling is extremely common. It is probably fair to state that in molecular hepatocarcinogenesis at least one of the discussed pathways has to be activated in a protumorigenic manner and that their multiple functions are indispensible for the development of the complete malignant phenotype. This hypothesis is strongly supported by several animal models. Nevertheless, future research will have to prove this hypothesis using representative HCC panels. Furthermore, it has to be tested whether the different pathways are completely redundant in terms of malignant progression and may freely compensate each other or whether certain specificities exist. 2. Constitutive activation multiple growth factor signaling pathways occurs at different levels. All the different types of changes have been observed in human HCCs, but pathway-specific patterns have appeared. Activation of IGF-II/IGFR/INSR signaling relies on increased ligand availability, whereas induction of the HGF/MET system is based on constitutive receptor activation either by overexpression or mutation. The physiological ligand HGF is of minor relevance. In contrast to this scenario, TGFb and Wnt pathways are typically dysregulated in downstream signaling components, for example, by mutations. The reasons for these pathway dependent differences are largely unknown so far; solving these questions is likely to offer new insights into the oncogenic mechanisms of growth factor dysregulation. 3. It has become clear that oncogenic growth factor signaling cannot be understood in the monodimensional manner of their canonical intracellular signaling pathways alone. Many different examples of cross-talk in growth factor signaling pathways with each other or with other oncogenic pathways, such as p53 or COX-2, have been demonstrated meanwhile. These connections are just beginning to unravel and will be a challenge to future functional studies and therapeutic interventions. 4. Several oncogenic dysregulations of growth factor signaling pathways offer promising therapeutic accessibility. These therapeutic interferences to date concentrate mainly on receptor kinases and may use small molecule inhibitors, inhibitory antibodies, specific chemotherapeutic agents and even gene therapy. These approaches have entered the clinic in various other malignancies and are likely to revolutionize the currently disappointing systemic therapy of HCC in many aspects, such as neoadjuvant therapy before resection and transplantation, adjuvant therapy and palliative treatment. The first functional studies have demonstrated the necessity to combine different approaches for optimal results and dose reduction.
Dysregulation of growth factor signaling in HCC has come a long way from a phenomenon seen as a curiosity without relevance or a reappearance of a fetal phenotype, comparable to AFP (alpha-Fetoprotein) expression, to an accepted protumorigenic mechanism worth being tackled by pharmaceutical approaches. Further surprises are likely to come.
